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A full-term newborn girl presenting with typical very
severe meconium aspiration syndrome (MAS) fulﬁlling
the criteria for extracorporeal membrane oxygenation
(ECMO) was successfully treated by surfactant lavage.
We wish to draw attention to this alternative treatment
option.
The patient’s 32-year-old G1P0 mother was admitted
to the labour ward at 41 weeks gestation for induction of
labour. Pregnancy was uneventful and fetal anatomy
and biometry were normal on ultrasound. A thick
meconium-stained amniotic ﬂuid was noted when
membranes ruptured. Fetal tachycardia necessitated a
caesarean section 2 h later. A baby girl was delivered
who was cyanotic, hypotonic and non reactive. The
heart rate was over 100/min (APGAR 2 at 1 min, 6 at
5 min and 7 at 10 min). Birth weight was 3170 g (P10–
P50), length 50 cm (P50) and cranial circumference
35.5 cm (P50–P90). Arterial and venous umbilical cord
blood gases were pH 7.07, BE -9 and pH 7.17, BE -7.8
respectively. In the absence of spontaneous breathing,
she was immediately intubated and the endotracheal
(ET) cannula withdrawn again under continuous suc-
tioning. Copious amounts of meconium were withdrawn
and as the heart rate remained above 100/min, a second
ET aspiration was performed through an ET tube but no
more meconium was removed. As the baby established
spontaneous breathing thereafter, nasal CPAP (PEEP
8 cm H2O) was initiated at FiO2 1.0 and rapidly reduced
to 0.6. Umbilical catheters were inserted and 10% glu-
cose was started concomitantly with antibiotics before
the baby was transferred to the neonatal intensive care
unit.
At 3 h of life, respiratory and cardiovascular condi-
tions worsened. Hypotension was treated with volume
expansion (0.9% NaCl, 10 ml/kg i.v.) and a continuous
dopamine infusion (10 lg/kg per min) as well as addi-
tion of dobutamine to stabilise blood pressure. Respi-
ratory distress worsened considerably with oxygen
requirements increasing to FiO2 1.0 to achieve a satu-
ration of 85%–90%. A chest X-ray ﬁlm showed typical
signs of severe MAS with a patchy pulmonary paren-
chyma and zones of hyperinﬂation and atelectasis.
Arterial blood gases with paO2 of 40.7 mmHg and pCO2
of 68 mmHg, BE -4.3 (OI 19.6) [6] required re-intuba-
tion after induction with morphine (0.1 mg/kg), mi-
dazolam (0.05 mg/kg) and pancuronium (0.1 mg/kg).
Ventilation was started on high frequency oscillation by
ﬁrst intention (MAP 23 cm H2O; Delta P 45 cm H2O;
FiO2 1.0, Sensormedics). The baby further deteriorated
and pulmonary hypertension was suspected on diﬀer-
entials of more than 10% between pre- and post-ductal
oxygen saturations and conﬁrmed on heart scan with a
right to left shunt over the ductus arteriosus.
At 9 h of life, FiO2 was still 0.8, MAP 23.5 cm H2O
and Delta P 52 cm H2O to achieve a paO2 of
25.6 mmHg and BE -2.3 (OI 73.4) (Fig. 1). Inhaled ni-
tric oxide (NO) was started at 5 ppm and rapidly raised
to 20 ppm. Intravenous morphine and repeated single
doses of pancuronium were given to optimise sedation.
Good but transitory improvement was noted after
starting NO. Despite deep sedation, pH >7.3 and NO,
respiratory distress worsened again and severe pulmo-
nary hypertension persisted.
At 26 h of life, the clinical condition showed no
improvement (FiO2 1.0, MAP 19.5 cm H2O, Delta P
55 cm H2O to achieve a paO2 of 36.4 mmHg, BE -3.3,
OI 53.6). The chest X-ray ﬁlm revealed a further increase
in hyperinﬂation.
MAS with OI >40 despite full conventional therapy
over several hours, is generally considered an indication
for ECMO [1]. However, ECMO in newborns is still
associated with a high morbidity and was unavailable in
Switzerland at that time. Furthermore, as the baby was
too unstable for transport to the closest European ECMO
centre, we opted for a broncho-alveolar lavage with
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diluted exogenous surfactant based on a small published
trial [3] using a protocol with a total volume of 15 ml/kg
(Curosurf 5 mg/ml diluted with 0.9%NaCl). We injected
24·2 ml aliquots of diluted surfactant through the side-
port of a 3.5 ET tube (Abbott) and re-aspirated through
theET tube as soon as ventilation parameters restabilised.
Short desaturations and transiently reduced ventilation
required a brief adaptation of ventilator settings, but no
haemodynamic or pulmonary complications resulted
from the procedure. Almost immediately after the pro-
cedure, the baby started to improve (OI 36.9 after 3 h; OI
7.8 after 24 h). Hyperinﬂation and atelectasis had disap-
peared on the chest X-ray ﬁlm 3 h later (Fig. 2) and it was
possible to wean and stop NO 16 h after the procedure.
The baby was extubated at 4 days of life (50 h after the
procedure); oxygenwas stopped on day 7 and nasal CPAP
on day 9. Brain scans remained normal as well as oto-
acoustic emissions. The baby was discharged home at 15
days of life.
Two randomised controlled trials have demonstrated
a reduction in the severity of the respiratory disease and
in the number of infants requiring ECMO after surfac-
tant replacement for severe MAS [2, 4]; however, mor-
tality remained unchanged. In cases with high mortality,
as indicated by ECMO criteria, broncho-alveolar lavage
may be superior to replacement therapy and present a
valuable alternative, particularly in situations and
countries where ECMO is not readily available for
newborns as well as in critical situations when the baby
is not stable enough for transport to an ECMO centre.
Little is known about surfactant lavage but it is cheap
and may prove as eﬀective as ECMO for the treatment
of severe MAS [5] when conventional therapy including
high frequency oscillation and NO fail. The eﬃcacy of
the treatment has been reported in several case reports
and in a small, randomised controlled trial [7] but for
establishment of the technique, randomisation versus
the standard ECMO technique is required. Nevertheless,
Fig. 2 Chest X-ray ﬁlms 20 h
before and 3 h after surfactant
lavage
Fig. 1 The course of OI from
birth to extubation
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this approach is worth considering when ECMO is
unavailable for the treatment of severe MAS.
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